Belantamab Mafodotin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), PHARMAC (New Zealand) and ZIN (Netherlands) recommended or restricted belantamab mafodotin, while DMC (Denmark) did not recommend it.
Assessment has run over 5.1 years, from 13 May 2021 at AWMSG (Wales) to 30 Jun 2026 at ZIN (Netherlands).
CIPM (Spain) changed its position: not recommended on 16 Dec 2021, recommended by 17 Jun 2026, after a resubmission.
No assessment is on file from HAS (France), PBAC (Australia), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for belantamab mafodotin, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 13 of 21 records date from 2023 or later.
Against its own class, belantamab mafodotin is an outlier: 43% of its decisive outcomes were positive, where molecules sharing ATC class L01X average 75%.
The programme is broad: 8 distinct indication wordings are recorded for belantamab mafodotin by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess belantamab mafodotin, on 13 May 2021; ZIN (Netherlands) did not open a file until 30 Jun 2026 — a wide spread of 5.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 9 of 19 dated records fall in 2026 alone.
5 of the 10 agencies here assessed belantamab mafodotin more than once, CIPM (Spain) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for belantamab mafodotin.
The full ledger for belantamab mafodotin reads 8 not recommended, 3 restricted, 3 recommended and 3 deferred to NICE, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 24 Jun 2026 | Belantamab mafodotin (Blenrep) i komb. m. bortezomib og dexamethason til voksne patienter med recidiveret eller refraktæ… | Ikke anbefalet, revurderes | source |
| CIPM (Spain) | 17 Jun 2026 | Indicaciones terapéuticas autorizadas: Blenrep está indicado en pacientes adultos para el tratamiento de mieloma múltipl… | financed by the SNS, on appeal · art. 92 a, c | source |
| PHARMAC (New Zealand) | 16 Jun 2026 | Multiple myeloma, relapsed or refractory, 2nd line or later | PTAC advice: High | source |
| NYE METODER (Norway) | 14 Jun 2026 | Kombinasjon med pomalidomid og deksametason for behandling av residiverende eller refraktær myelomatose hos pasienter so… | introduced | source |
| NICE (England) | 30 Apr 2026 | NICE TA1149 | published appraisal | source |
16 further decisions for belantamab mafodotin, across 8 agencies, are not shown here. They include the most recent record on file, 30 Jun 2026 from ZIN (Netherlands); its outcome is in the subscriber dataset. They link to 16 further source documents.
Related molecules
- panobinostat — divergent outcome (not recommended vs recommended) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
Coverage: 21 decisions for belantamab mafodotin from 10 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.